Table 1 Characteristics of women with SLE and healthy controls
|  | Women with SLE (n = 69) | Healthy women (n = 27) |
|---|---|---|
Age (years), median (range)a | 32 (23–43) | 29 (24–41) |
Nulliparous, n (%) | 41 (59) | 21 (78) |
Disease duration at inclusion (years), median (range) | 9 (0–26) |  |
SLEDAI-2K during pregnancy, median (range)b | 1 (0–14) |  |
ACR criteria ever, n (%) | ||
 Malar Rash | 28 (41) |  |
 Discoid rash | 4 (6) |  |
 Photosensitivity | 35 (51) |  |
 Oral ulcers | 28 (41) |  |
 Arthritis | 58 (84) |  |
 Serositis | 12 (17) |  |
 Renal disorder | 26 (38) |  |
 Neurological disorder | 4 (6) |  |
 Hematological disorder | 41 (59) |  |
 Immunological disorder | 59 (86) |  |
 ANA | 68 (99) |  |
Autoantibodies ever, n (%) | ||
 Anti-dsDNA | 58 (84) |  |
 Anti-Smc | 19 (28) |  |
 Anti-SSA | 22 (32) |  |
 Anti-SSB | 12 (17) |  |
 Lupus anticoagulant | 11 (16) |  |
 Anti-cardiolipin IgG | 10 (15) |  |
 Anti-β2glycoprotein I IgGc | 11 (16) |  |
 Ever antiphospholipid antibodies | 17 (25) |  |
Antiphospholipid syndrome, n (%) | 4 (6) | Â |
Medication in early pregnancy, n (%) | ||
 Hydroxychloroquine or chloroquine phosphate | 63 (91) |  |
 Acetylsalicylic acid | 60 (87) |  |
 Low molecular weight heparin | 14 (20) |  |
 Azathioprine | 20 (29) |  |
 Prednisone | 18 (26) |  |